Eva Lesén1, Daniel Granfeldt2, Aude Houchard3, Jérôme Dinet3, Anthony Berthon3, Daniel S Olsson4, Ingela Björholt2, Gudmundur Johannsson4. 1. Nordic Health EconomicsGothenburg, Sweden eva.lesen@nordichealtheconomics.se. 2. Nordic Health EconomicsGothenburg, Sweden. 3. IpsenBoulogne-Billancourt, France. 4. Department of Internal Medicine and Clinical NutritionInstitute of Medicine, Sahlgrenska Academy, University of Gothenburg and Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Abstract
OBJECTIVE: Acromegaly is a complex endocrine disease with multiple comorbidities. Treatment to obtain biochemical remission includes surgery, medical therapy and radiation. We aimed to describe comorbidities, treatment patterns and cost-of-illness in patients with acromegaly in Sweden. DESIGN: A nationwide population-based study. METHODS: Patients with acromegaly were identified and followed in national registers in Sweden. Longitudinal treatment patterns were assessed in patients diagnosed between July 2005 and December 2013. The cost-of-illness during 2013 was estimated from a societal perspective among patients diagnosed between 1987 and 2013. RESULTS: Among 358 patients with acromegaly (48% men, mean age at diagnosis 50.0 (s.d. 15.3) years) at least one comorbidity was reported in 81% (n = 290). The most common comorbidities were hypertension (40%, n = 142), neoplasms outside the pituitary (30%, n = 109), hypopituitarism (22%, n = 80) and diabetes mellitus (17%, n = 61). Acromegaly treatment was initiated on average 3.7 (s.d. 6.9) months after diagnosis. Among the 301 treated patients, the most common first-line treatments were surgery (60%, n = 180), somatostatin analogues (21%, n = 64) and dopamine agonists (14%, n = 41). After primary surgery, 24% (n = 44) received somatostatin analogues. The annual per-patient cost was €12 000; this was €8700 and €16 000 if diagnosed before or after July 2005, respectively. The cost-of-illness for acromegaly and its comorbidities was 77% from direct costs and 23% from production loss. CONCLUSIONS: The prevalence of comorbidity is high in patients with acromegaly. The most common first-line treatment in acromegalic patients was surgery followed by somatostatin analogues. The annual per-patient cost of acromegaly and its comorbidities was €12 000.
OBJECTIVE:Acromegaly is a complex endocrine disease with multiple comorbidities. Treatment to obtain biochemical remission includes surgery, medical therapy and radiation. We aimed to describe comorbidities, treatment patterns and cost-of-illness in patients with acromegaly in Sweden. DESIGN: A nationwide population-based study. METHODS:Patients with acromegaly were identified and followed in national registers in Sweden. Longitudinal treatment patterns were assessed in patients diagnosed between July 2005 and December 2013. The cost-of-illness during 2013 was estimated from a societal perspective among patients diagnosed between 1987 and 2013. RESULTS: Among 358 patients with acromegaly (48% men, mean age at diagnosis 50.0 (s.d. 15.3) years) at least one comorbidity was reported in 81% (n = 290). The most common comorbidities were hypertension (40%, n = 142), neoplasms outside the pituitary (30%, n = 109), hypopituitarism (22%, n = 80) and diabetes mellitus (17%, n = 61). Acromegaly treatment was initiated on average 3.7 (s.d. 6.9) months after diagnosis. Among the 301 treated patients, the most common first-line treatments were surgery (60%, n = 180), somatostatin analogues (21%, n = 64) and dopamine agonists (14%, n = 41). After primary surgery, 24% (n = 44) received somatostatin analogues. The annual per-patient cost was €12 000; this was €8700 and €16 000 if diagnosed before or after July 2005, respectively. The cost-of-illness for acromegaly and its comorbidities was 77% from direct costs and 23% from production loss. CONCLUSIONS: The prevalence of comorbidity is high in patients with acromegaly. The most common first-line treatment in acromegalicpatients was surgery followed by somatostatin analogues. The annual per-patient cost of acromegaly and its comorbidities was €12 000.
Authors: Sjorjina Crowther; R Louise Rushworth; Wayne Rankin; Henrik Falhammar; Liza K Phillips; David J Torpy Journal: Endocrine Date: 2017-11-04 Impact factor: 3.633
Authors: Patrick Petrossians; Adrian F Daly; Emil Natchev; Luigi Maione; Karin Blijdorp; Mona Sahnoun-Fathallah; Renata Auriemma; Alpha M Diallo; Anna-Lena Hulting; Diego Ferone; Vaclav Hana; Silvia Filipponi; Caroline Sievers; Claudia Nogueira; Carmen Fajardo-Montañana; Davide Carvalho; Vaclav Hana; Günter K Stalla; Marie-Lise Jaffrain-Réa; Brigitte Delemer; Annamaria Colao; Thierry Brue; Sebastian J C M M Neggers; Sabina Zacharieva; Philippe Chanson; Albert Beckers Journal: Endocr Relat Cancer Date: 2017-07-21 Impact factor: 5.678
Authors: Konstantina Vouzouneraki; Karl A Franklin; Maria Forsgren; Maria Wärn; Jenny Tiberg Persson; Helena Wik; Christina Dahlgren; Ann-Sofie Nilsson; Caroline Alkebro; Pia Burman; Eva-Marie Erfurth; Jeanette Wahlberg; Anna-Karin Åkerman; Charlotte Høybye; Oskar Ragnarsson; Britt Edén Engström; Per Dahlqvist Journal: Endocrine Date: 2018-07-31 Impact factor: 3.633
Authors: Daniel J Lobatto; Wilbert B van den Hout; Amir H Zamanipoor Najafabadi; Anath N V Steffens; Cornelie D Andela; Alberto M Pereira; Wilco C Peul; Wouter R van Furth; Nienke R Biermasz; Thea P M Vliet Vlieland Journal: Endocrine Date: 2019-03-22 Impact factor: 3.633
Authors: Maria Kamusheva; Silvia Vandeva; Konstantin Mitov; Yanitsa Rusenova; Atanaska Elenkova; Sabina Zacharieva; Zornitsa Mitkova; Konstantin Tachkov; Maria Dimitrova; Miglena Doneva; Dimitar Tcharaktchiev; Guenka Petrova Journal: Front Public Health Date: 2020-04-28